Endocrine Abstracts

Context: Acromegaly is chronic insidious disease caused by excessive GH secretion by pituitary adenoma. This leads to overproduction of IGF1 and serious disseminated concequences.Material: 14 acromegalic subjects with diagnosed insulin dependent diabetes on stable octreotide LAR) treatment. Patients did not meet recent criteria of biochemical controlled disease (mean GH 4.6 ng/ml, mean IGF1 2.2-fold upper normal limit).Methods: Pat...

Background: Neurosurgery is treatment of choice in patients with GH-secreting pituitary adenoma. However, in about 50% of cases surgery is ineffective or contraindicated. Long-acting somatostatin analogues are possible, although expensive therapeutic alternative. Generally, 60–70% of patients with active disease responds to such medical treatment.Aim: Aim of this study was to identify factors influencing medical treatment outcome and to determine if...

Background: Insulin resistance leading to glucose intolerance and even diabetes mellitus is common in acromegaly and is partially caused by pathological high concentrations of growth hormone (GH) and somatomedin C (IGF-1). On the other hand, somatostatin analogues, common treatment option, can cause inhibition of insulin secretion and glucose tolerance disturbances.Aim: Of the study was to determine impact of prolonged somatostatin analogues administrati...

Introduction: Generously supported by IPSEN)-->Impaired glucose tolerance and insulin resistance are frequently associated with acromegaly. The aim of this study was to assess the effect of octreotide-LAR treatment on glucose homeostasis in acromegalic patients.Patients and methods: In this prospective study 16 naïve acromegalic patients were studied before and after 3-month therapy of octreotide-LAR (20 m...

Background: Acromegaly is characterized by disabling symptoms and relevant comorbidities. Insulin resistance, leading to glucose intolerance is one of the most important contributory factor to the cardiovascular mortality in acromegaly.Aim: To assess the impairments of glucose homeostasis in acromegalic patients and find association between activity of the disease and the severity of glucose intolerance.Patients and methods: In thi...

Background: TSH-secreting tumors appears as extremely rare cause of hyperthyroidism. Major clinical feature is preserved TSH level in subjects with apparent thyrotoxicosis. Misdiagnosis of primary thyroid hyper function led to mistreatment with anti-thyroid agents. This worsens disease course and outcome. Neurosurgery success rate is limited by large tumor size and extrasellular expansion. Somatostatin plays key role in regulation of TSH secretion. Tumors in most cases express...

Introduction: Impaired glucose tolerance and overt diabetes mellitus are frequently associated with acromegaly. The aim of this study was to find whether these alterations could be reversed after transsphenoidal surgery.Patients and methods: Two hundred and thirty-nine acromegalic patients were studied before and 6–12 months after transsphenoidal surgery. Diagnosis of active acromegaly was established on the basis of widely recognized criteria. In e...

Introduction: Transsphenoidal adenomectomy is the treatment of choice in secreting pituitary adenomas with the symptoms of Cushing’s disease, acromegaly as well as few cases of Prolactinoma, which – due to resistance to pharmacological treatment – require surgery. The efficacy of selective adenomectomy ranges from 60 to 95%. It is the highest in patients with well-visualized by MRI microadenomas, lower in macroadenomas and the lowest when the surgery was ...

Background: MEN1 is an autosomal dominant inherited syndrome. Primary hyperparathyroidism, tumors of the endocrine pancreas, and of the pituitary, are the characteristic features of the syndrome.Objective: To present a case of MEN1 in a patient with extreme obesity, causing serious difficulties in diagnostic procedures leading to localization of pancreatic tumors.Case presentation: 22-year-old male with extreme obesity (BMI 59), hy...

Aim: The aim of multi-center, observational study was to assess the outcome of the treatment with somatostatin analogue octreotide-LAR (O-LAR) patients with acromegaly.Material: Material consisted of 360 patients (60% women) aged 18–84 years (mean 45.5; S.D.±12.9) with active acromegaly. Prior to the inclusion 172 patients underwent unsuccessful neurosurgery.Methods: Observation was planned for 1 year. O-LA...